Allos AI
Oxford, UK· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
An AI-driven biotech discovering novel targets and mechanisms for next-generation cancer immunotherapies.
OncologyImmunology
Technology Platform
An AI platform that analyzes multi-omics data to discover novel immune-oncology targets and therapeutic mechanisms beyond current checkpoint inhibitors.
Opportunities
Successfully identifying and validating a novel, druggable immuno-oncology target could lead to a lucrative partnership or acquisition.
Risk Factors
High risk of platform validation; AI-generated hypotheses may not translate into biologically effective or druggable targets in the lab.
Competitive Landscape
Operates in a crowded field of AI-driven drug discovery startups, requiring exceptional biological validation to stand out.